Is outcomes-based contracting worth it?

New York Times and ProPublica
July 12, 2017

Following an op-ed by Anna Kaltenboeck and Dr. Peter Bach in Morning Consult, the New York Times and ProPublica take a closer look at the potential costs and benefits of outcomes-based contracting. “Dr. Bach and others say the pharmaceutical industry is using this approach to justify major changes in federal regulations […] The industry says the changes are needed to allow more flexibility in the type of deals they offer.”